Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-07T00:00:42.253Z Has data issue: false hasContentIssue false
  • English
  • Français

Trazodone Augmentation in OCD: A Case Series Report

Published online by Cambridge University Press:  07 November 2014

Donatella Marazziti ,
Alfredo Gemignani  and
Liliana Dell'Osso
Get access Rights & Permissions [Opens in a new window]

Abstract

Based on previous evidence that trazodone may have antiobsessional properties, the authors assessed trazodone augmentation of selective serotonin reuptake inhibitor (SSRI) therapy in five cases of obsessive-compulsive disorder. All patients showed symptomatic improvement after trazodone was added to treatment with various SSRIs, and in many cases, trazodone also improved the tolerability of SSRI therapy.

Type
Feature Articles—Original Research
Information
CNS Spectrums , Volume 4 , Issue 12: Social Phobia , December 1999 , pp. 48 - 49
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Maj, J, Palider, W, Rawlow, J. Trazodone, a central serotonin antagonist and agonist. J Neural Transm Gen Sect. 1979;44:237–248.CrossRefGoogle ScholarPubMed
2.Zohar, J, Insel, TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry. 1987;2:667–687.CrossRefGoogle Scholar
3.Hollander, E, Fay, M, Cohen, B, Campeas, R, Gorman, JM, Liebowitz, MR. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder behavioral findings. Arch Gen Psychiatry. 1988;145:1015–1023.Google ScholarPubMed
4.Prasad, AJ. Obsessive-compulsive disorder and trazodone [letter]. Am J Psychiatry. 1984;141:612–613.Google ScholarPubMed
5.Baxter, L. Two cases of obsessive-compulsive disorder with depression responsive to trazodone. J Nerv Ment Dis. 1985;173:432–433.CrossRefGoogle ScholarPubMed
6.Lydiard, RB. Obsessive-compulsive disorder successfully treated with trazodone. Psychosomatics. 1986;27:858–859.CrossRefGoogle ScholarPubMed
7.Kim, SW. Trazodone in the treatment of obsessive-compulsive disorder a case report ]letter]. J Clin Psychopharmacol. 1987;7:278–279.CrossRefGoogle Scholar
8.Ramchandani, D. Trazodone for bowel obsession [letter]. Am J Psychiatry. 1990;147:124.Google ScholarPubMed
9.Sunkureddi, K, Markovitz, P. Trazodone treatment of obsessive-compulsive disorder and tricotillomania [letter]. Am J Psychiatry. 1993;150:523–524.Google Scholar
10.Prasad, A. Efficacy of trazodone as an anti-obsessional agent. Neuropsychobiology. 1986;15:19–21.CrossRefGoogle ScholarPubMed
11.Hermesh, H, Aizenberg, D, Munitz, H. Trazodone treatment in clomipramine-resistant obsesssive-compulsive disorder. Clin Neuropharmacol. 1990;13:322–328.CrossRefGoogle ScholarPubMed
12.Mattes, JA. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1986;1:170–173.CrossRefGoogle ScholarPubMed
13.Pigott, TA, L'Hereueux, F, Rubenstein, CS. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12:156–162.Google ScholarPubMed
14.Goodman, WK, Price, LH, Rasmussen, SA. The Yale-Brown Obsessive Compulsive Scale I: development, use and reliability. Arch Gen Psychiatry. 1996;46:1006–1011.CrossRefGoogle Scholar
15.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:189–192.CrossRefGoogle ScholarPubMed
16.Lawlor, BA, Radcliffe, J, Martinez, R, et al.Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chorophenylpiperazine and trazodone in healthy volunteers. Biol Psychiatry. 1997;41:756–757.CrossRefGoogle Scholar